Patient/advocate Diane Redington and Dr. Whitfield Growden discuss the management of ovarian and uterine carcinosarcoma. This is part four of a nine part series. Dr. Growden discusses important differences between ovarian and uterine carcinosarcoma and takes us through the stages of ovarian and uterine carcinosarcoma cancers and treatment modalities for each at the various stages. […]
During a round table discussion on One Live TV, Michael J. Birrer, MD, PhD, explains new research for ovarian cancer in non-platinum-based chemotherapies, particularly PARP inhibition. Published on Apr 22, 2015.
In this video from Mass General Hospital from May 2016, it was announced that Phase II funding had been received for a multi-institution project to study patients who have survived ovarian cancer for 10 or more years. Published on May 6, 2016.
In this video, Dr. Michael Birrer talks about targeting either VEGF or ANG2 in gynecologic cancers. VEGF stimulates tumor vessel growth, while ANG2 stabilizes the vessels. Published on Nov 25, 2015.
In this video from Onc Live TV, Dr. Birrer discusses how progression-free survival and overall survival are holding back the approval of drugs for ovarian cancer patients. Published on Oct 16, 2013.
In this lecture from January 2013 by Dr. Michael Birrer, prospects for targeted therapy in ovarian cancer are discussed. Published on Jan 21, 2013.